chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: M
Vaccine: FLU3, HEPA, MMR, VARCEL
Symptoms: Convulsion, Crying, Culture urine negative, Dyskinesia, Dyspnoea
Clinical narrative: This serious case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 299441). A male patient (age not reported) had received a first dose injection of FLUZONE, lot number UT2460F, a first dose injection of HAVRIX (manufacturer GlaxoSmithKline, lot number AHAVB200AA), a first dose injection of MMR, (manufacturer Merck, lot number 1351U), and a first dose injection of VARIVAX, (manufacturer Merck, lot number 0426U) on 22 October 2007. On the day of vaccination, the patient was noted to have had thick eye discharge, but otherwise in good health and meeting developmental milestones. Per parent report, the patient experienced a high fever for several days after vaccination, and displayed rapid and uncontrollable shaking and seizure like episodes that resulted n the patient being hospitalized. He also experienced breathing difficulty, drowsiness and excessive crankiness and crying. According to medical records, the patient had thick eye discharge on the day of vaccination (22 October 2007). He was diagnosed with conjunctivitis and prescribed eye drops. On 31 October 2007, nine days after receiving the vaccines, the patient returned to their physician with vomiting, lethargy, fever, dyspnea, reduced oral intake, and not acting himself x three days. He was diagnosed with viral disease. The patient was admitted to the hospital that same day with fever and upper respiratory infection (URI). According to hospital records for dates of service 31 October 2007 to 01 November 2007, the patient developed a low grade fever (99-100) and cold symptoms five days prior to admission. He also experienced abnormal movements and slow rhythmic body contractions followed by drowsiness. He was sent to day care and continued to have jerky movements and was noted to have a wide based gait when taken to his primary care physician on the day of hospitalization. On the day of admission, he had vomiting and a max temperature of 102. Fluid collection in the right ear was found upon examination. A chest x-ray was normal; stool "guaic" negative; urine and blood C/S (cultures and sensitivity) negative. The final diagnosis was viral syndrome. On 26 November 2007, the patient returned to their physician with purulent discharge from the eyes x 3 days, nasal discharge x 4 days and cough. He was diagnosed with conjunctivitis and otitis media of the right ear and antibiotics were prescribed. The outcome for the event was reported as life-threatening, hospitalized, and emergency room or doctor visit (ER). The patients recovery status was not reported. The events of conjunctivitis infective and conjunctivitis were included in the coding from the VAERS database; however only the event of conjunctivitis was mentioned in the narrative. Documents held by sender: None.
Sex: M
Vaccine: FLU3, HEPA, MMR, VARCEL
Symptoms: Eye discharge, Gait disturbance, Hypophagia, Irritability, Lethargy
Clinical narrative: This serious case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 299441). A male patient (age not reported) had received a first dose injection of FLUZONE, lot number UT2460F, a first dose injection of HAVRIX (manufacturer GlaxoSmithKline, lot number AHAVB200AA), a first dose injection of MMR, (manufacturer Merck, lot number 1351U), and a first dose injection of VARIVAX, (manufacturer Merck, lot number 0426U) on 22 October 2007. On the day of vaccination, the patient was noted to have had thick eye discharge, but otherwise in good health and meeting developmental milestones. Per parent report, the patient experienced a high fever for several days after vaccination, and displayed rapid and uncontrollable shaking and seizure like episodes that resulted n the patient being hospitalized. He also experienced breathing difficulty, drowsiness and excessive crankiness and crying. According to medical records, the patient had thick eye discharge on the day of vaccination (22 October 2007). He was diagnosed with conjunctivitis and prescribed eye drops. On 31 October 2007, nine days after receiving the vaccines, the patient returned to their physician with vomiting, lethargy, fever, dyspnea, reduced oral intake, and not acting himself x three days. He was diagnosed with viral disease. The patient was admitted to the hospital that same day with fever and upper respiratory infection (URI). According to hospital records for dates of service 31 October 2007 to 01 November 2007, the patient developed a low grade fever (99-100) and cold symptoms five days prior to admission. He also experienced abnormal movements and slow rhythmic body contractions followed by drowsiness. He was sent to day care and continued to have jerky movements and was noted to have a wide based gait when taken to his primary care physician on the day of hospitalization. On the day of admission, he had vomiting and a max temperature of 102. Fluid collection in the right ear was found upon examination. A chest x-ray was normal; stool "guaic" negative; urine and blood C/S (cultures and sensitivity) negative. The final diagnosis was viral syndrome. On 26 November 2007, the patient returned to their physician with purulent discharge from the eyes x 3 days, nasal discharge x 4 days and cough. He was diagnosed with conjunctivitis and otitis media of the right ear and antibiotics were prescribed. The outcome for the event was reported as life-threatening, hospitalized, and emergency room or doctor visit (ER). The patients recovery status was not reported. The events of conjunctivitis infective and conjunctivitis were included in the coding from the VAERS database; however only the event of conjunctivitis was mentioned in the narrative. Documents held by sender: None.
Sex: M
Vaccine: FLU3, HEPA, MMR, VARCEL
Symptoms: Muscle contractions involuntary, Occult blood negative, Otitis media, Pyrexia, Somnolence
Clinical narrative: This serious case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 299441). A male patient (age not reported) had received a first dose injection of FLUZONE, lot number UT2460F, a first dose injection of HAVRIX (manufacturer GlaxoSmithKline, lot number AHAVB200AA), a first dose injection of MMR, (manufacturer Merck, lot number 1351U), and a first dose injection of VARIVAX, (manufacturer Merck, lot number 0426U) on 22 October 2007. On the day of vaccination, the patient was noted to have had thick eye discharge, but otherwise in good health and meeting developmental milestones. Per parent report, the patient experienced a high fever for several days after vaccination, and displayed rapid and uncontrollable shaking and seizure like episodes that resulted n the patient being hospitalized. He also experienced breathing difficulty, drowsiness and excessive crankiness and crying. According to medical records, the patient had thick eye discharge on the day of vaccination (22 October 2007). He was diagnosed with conjunctivitis and prescribed eye drops. On 31 October 2007, nine days after receiving the vaccines, the patient returned to their physician with vomiting, lethargy, fever, dyspnea, reduced oral intake, and not acting himself x three days. He was diagnosed with viral disease. The patient was admitted to the hospital that same day with fever and upper respiratory infection (URI). According to hospital records for dates of service 31 October 2007 to 01 November 2007, the patient developed a low grade fever (99-100) and cold symptoms five days prior to admission. He also experienced abnormal movements and slow rhythmic body contractions followed by drowsiness. He was sent to day care and continued to have jerky movements and was noted to have a wide based gait when taken to his primary care physician on the day of hospitalization. On the day of admission, he had vomiting and a max temperature of 102. Fluid collection in the right ear was found upon examination. A chest x-ray was normal; stool "guaic" negative; urine and blood C/S (cultures and sensitivity) negative. The final diagnosis was viral syndrome. On 26 November 2007, the patient returned to their physician with purulent discharge from the eyes x 3 days, nasal discharge x 4 days and cough. He was diagnosed with conjunctivitis and otitis media of the right ear and antibiotics were prescribed. The outcome for the event was reported as life-threatening, hospitalized, and emergency room or doctor visit (ER). The patients recovery status was not reported. The events of conjunctivitis infective and conjunctivitis were included in the coding from the VAERS database; however only the event of conjunctivitis was mentioned in the narrative. Documents held by sender: None.
Sex: M
Vaccine: FLU3, HEPA, MMR, VARCEL
Symptoms: Tremor, Upper respiratory tract infection, Viral infection, Vomiting
Clinical narrative: This serious case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 299441). A male patient (age not reported) had received a first dose injection of FLUZONE, lot number UT2460F, a first dose injection of HAVRIX (manufacturer GlaxoSmithKline, lot number AHAVB200AA), a first dose injection of MMR, (manufacturer Merck, lot number 1351U), and a first dose injection of VARIVAX, (manufacturer Merck, lot number 0426U) on 22 October 2007. On the day of vaccination, the patient was noted to have had thick eye discharge, but otherwise in good health and meeting developmental milestones. Per parent report, the patient experienced a high fever for several days after vaccination, and displayed rapid and uncontrollable shaking and seizure like episodes that resulted n the patient being hospitalized. He also experienced breathing difficulty, drowsiness and excessive crankiness and crying. According to medical records, the patient had thick eye discharge on the day of vaccination (22 October 2007). He was diagnosed with conjunctivitis and prescribed eye drops. On 31 October 2007, nine days after receiving the vaccines, the patient returned to their physician with vomiting, lethargy, fever, dyspnea, reduced oral intake, and not acting himself x three days. He was diagnosed with viral disease. The patient was admitted to the hospital that same day with fever and upper respiratory infection (URI). According to hospital records for dates of service 31 October 2007 to 01 November 2007, the patient developed a low grade fever (99-100) and cold symptoms five days prior to admission. He also experienced abnormal movements and slow rhythmic body contractions followed by drowsiness. He was sent to day care and continued to have jerky movements and was noted to have a wide based gait when taken to his primary care physician on the day of hospitalization. On the day of admission, he had vomiting and a max temperature of 102. Fluid collection in the right ear was found upon examination. A chest x-ray was normal; stool "guaic" negative; urine and blood C/S (cultures and sensitivity) negative. The final diagnosis was viral syndrome. On 26 November 2007, the patient returned to their physician with purulent discharge from the eyes x 3 days, nasal discharge x 4 days and cough. He was diagnosed with conjunctivitis and otitis media of the right ear and antibiotics were prescribed. The outcome for the event was reported as life-threatening, hospitalized, and emergency room or doctor visit (ER). The patients recovery status was not reported. The events of conjunctivitis infective and conjunctivitis were included in the coding from the VAERS database; however only the event of conjunctivitis was mentioned in the narrative. Documents held by sender: None.
Age: 1.0
Sex: M
Vaccine: DTAP, FLU3, HIBV, IPV, PNC, DTAP, FLU3, HIBV, IPV, PNC
Symptoms: Aspartate aminotransferase increased, Blood culture negative, Blood electrolytes normal, Blood product transfusion, Bronchiolitis
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 306745). A one-year-old male patient received the following vaccinations on 20 February 2008: a third intramuscular injection of DAPTACEL (lot number C2800AA); a second intramuscular injection of FLUZONE No Preservative (lot number UT2459LB); a third subcutaneous injection of IPOL (lot number A0169-2); a third intramuscular injection of PREVNAR (Wyeth, lot number C45150); and a third intramuscular injection of PEDVAXHIB (Merck, lot number 0076U). The following day, the patient fell at home and hit his head, and later presented to the emergency room with a fever. The following day he presented to the emergency department again with fever (103.1) and upper respiratory infection symptoms including cough, post tussive emesis, and irritability. It was noted that he had a sick sibling at home. He was treated with intravenous antibiotics and antipyretics, and discharge to home. The next day, on 23 February 2008, he was seen by his primary care physician with respiratroy congestion, wheezing, and intercostal retractions. He was admitted to the hospital at that time with additional symptoms of bronchiolitis, conjunctivitis, otitis media, irritability, and poor appetite. He was initially treated with breathing treatments and intravenous antibiotics. During the course of this hospitalization he developed a diffuse urticarial rash, inflamed conjunctiva, swelling of the hands and feet, peeling skin on the feet, and red lips. His fever increased to 106 degrees, and on 28 February 2008 he was transferred to a higher level of care. Laboratory testing at that time revealed the following: CRP 273, WBC 26,000, platelets 718,000, SGOT 44; electrolytes and echocardiogram were within normal limits, and viral testing and blood cultures were negative. Cardiology was consulted, and he was diagnosed with atypical KAWASAKI's disease without evidence of cardiac lesions. He was treated with intravenous immunoglobulins and aspirin, after which he improved and was discharged to home on 03 March 2008 with instructions to follow-up for serial echocardiograms. The event was considered to be recovered.
Age: 1.0
Sex: M
Vaccine: DTAP, FLU3, HIBV, IPV, PNC, DTAP, FLU3, HIBV, IPV, PNC
Symptoms: C-reactive protein increased, Cheilitis, Conjunctivitis, Cough, Decreased appetite
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 306745). A one-year-old male patient received the following vaccinations on 20 February 2008: a third intramuscular injection of DAPTACEL (lot number C2800AA); a second intramuscular injection of FLUZONE No Preservative (lot number UT2459LB); a third subcutaneous injection of IPOL (lot number A0169-2); a third intramuscular injection of PREVNAR (Wyeth, lot number C45150); and a third intramuscular injection of PEDVAXHIB (Merck, lot number 0076U). The following day, the patient fell at home and hit his head, and later presented to the emergency room with a fever. The following day he presented to the emergency department again with fever (103.1) and upper respiratory infection symptoms including cough, post tussive emesis, and irritability. It was noted that he had a sick sibling at home. He was treated with intravenous antibiotics and antipyretics, and discharge to home. The next day, on 23 February 2008, he was seen by his primary care physician with respiratroy congestion, wheezing, and intercostal retractions. He was admitted to the hospital at that time with additional symptoms of bronchiolitis, conjunctivitis, otitis media, irritability, and poor appetite. He was initially treated with breathing treatments and intravenous antibiotics. During the course of this hospitalization he developed a diffuse urticarial rash, inflamed conjunctiva, swelling of the hands and feet, peeling skin on the feet, and red lips. His fever increased to 106 degrees, and on 28 February 2008 he was transferred to a higher level of care. Laboratory testing at that time revealed the following: CRP 273, WBC 26,000, platelets 718,000, SGOT 44; electrolytes and echocardiogram were within normal limits, and viral testing and blood cultures were negative. Cardiology was consulted, and he was diagnosed with atypical KAWASAKI's disease without evidence of cardiac lesions. He was treated with intravenous immunoglobulins and aspirin, after which he improved and was discharged to home on 03 March 2008 with instructions to follow-up for serial echocardiograms. The event was considered to be recovered.
Age: 1.0
Sex: M
Vaccine: DTAP, FLU3, HIBV, IPV, PNC, DTAP, FLU3, HIBV, IPV, PNC
Symptoms: Echocardiogram normal, Fall, Head injury, Irritability, Kawasaki's disease
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 306745). A one-year-old male patient received the following vaccinations on 20 February 2008: a third intramuscular injection of DAPTACEL (lot number C2800AA); a second intramuscular injection of FLUZONE No Preservative (lot number UT2459LB); a third subcutaneous injection of IPOL (lot number A0169-2); a third intramuscular injection of PREVNAR (Wyeth, lot number C45150); and a third intramuscular injection of PEDVAXHIB (Merck, lot number 0076U). The following day, the patient fell at home and hit his head, and later presented to the emergency room with a fever. The following day he presented to the emergency department again with fever (103.1) and upper respiratory infection symptoms including cough, post tussive emesis, and irritability. It was noted that he had a sick sibling at home. He was treated with intravenous antibiotics and antipyretics, and discharge to home. The next day, on 23 February 2008, he was seen by his primary care physician with respiratroy congestion, wheezing, and intercostal retractions. He was admitted to the hospital at that time with additional symptoms of bronchiolitis, conjunctivitis, otitis media, irritability, and poor appetite. He was initially treated with breathing treatments and intravenous antibiotics. During the course of this hospitalization he developed a diffuse urticarial rash, inflamed conjunctiva, swelling of the hands and feet, peeling skin on the feet, and red lips. His fever increased to 106 degrees, and on 28 February 2008 he was transferred to a higher level of care. Laboratory testing at that time revealed the following: CRP 273, WBC 26,000, platelets 718,000, SGOT 44; electrolytes and echocardiogram were within normal limits, and viral testing and blood cultures were negative. Cardiology was consulted, and he was diagnosed with atypical KAWASAKI's disease without evidence of cardiac lesions. He was treated with intravenous immunoglobulins and aspirin, after which he improved and was discharged to home on 03 March 2008 with instructions to follow-up for serial echocardiograms. The event was considered to be recovered.
Age: 1.0
Sex: M
Vaccine: DTAP, FLU3, HIBV, IPV, PNC, DTAP, FLU3, HIBV, IPV, PNC
Symptoms: Oedema peripheral, Otitis media, Platelet count increased, Post-tussive vomiting, Pyrexia
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 306745). A one-year-old male patient received the following vaccinations on 20 February 2008: a third intramuscular injection of DAPTACEL (lot number C2800AA); a second intramuscular injection of FLUZONE No Preservative (lot number UT2459LB); a third subcutaneous injection of IPOL (lot number A0169-2); a third intramuscular injection of PREVNAR (Wyeth, lot number C45150); and a third intramuscular injection of PEDVAXHIB (Merck, lot number 0076U). The following day, the patient fell at home and hit his head, and later presented to the emergency room with a fever. The following day he presented to the emergency department again with fever (103.1) and upper respiratory infection symptoms including cough, post tussive emesis, and irritability. It was noted that he had a sick sibling at home. He was treated with intravenous antibiotics and antipyretics, and discharge to home. The next day, on 23 February 2008, he was seen by his primary care physician with respiratroy congestion, wheezing, and intercostal retractions. He was admitted to the hospital at that time with additional symptoms of bronchiolitis, conjunctivitis, otitis media, irritability, and poor appetite. He was initially treated with breathing treatments and intravenous antibiotics. During the course of this hospitalization he developed a diffuse urticarial rash, inflamed conjunctiva, swelling of the hands and feet, peeling skin on the feet, and red lips. His fever increased to 106 degrees, and on 28 February 2008 he was transferred to a higher level of care. Laboratory testing at that time revealed the following: CRP 273, WBC 26,000, platelets 718,000, SGOT 44; electrolytes and echocardiogram were within normal limits, and viral testing and blood cultures were negative. Cardiology was consulted, and he was diagnosed with atypical KAWASAKI's disease without evidence of cardiac lesions. He was treated with intravenous immunoglobulins and aspirin, after which he improved and was discharged to home on 03 March 2008 with instructions to follow-up for serial echocardiograms. The event was considered to be recovered.
Age: 1.0
Sex: M
Vaccine: DTAP, FLU3, HIBV, IPV, PNC, DTAP, FLU3, HIBV, IPV, PNC
Symptoms: Respiratory tract congestion, Sick relative, Skin exfoliation, Upper respiratory tract infection, Urticaria
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 306745). A one-year-old male patient received the following vaccinations on 20 February 2008: a third intramuscular injection of DAPTACEL (lot number C2800AA); a second intramuscular injection of FLUZONE No Preservative (lot number UT2459LB); a third subcutaneous injection of IPOL (lot number A0169-2); a third intramuscular injection of PREVNAR (Wyeth, lot number C45150); and a third intramuscular injection of PEDVAXHIB (Merck, lot number 0076U). The following day, the patient fell at home and hit his head, and later presented to the emergency room with a fever. The following day he presented to the emergency department again with fever (103.1) and upper respiratory infection symptoms including cough, post tussive emesis, and irritability. It was noted that he had a sick sibling at home. He was treated with intravenous antibiotics and antipyretics, and discharge to home. The next day, on 23 February 2008, he was seen by his primary care physician with respiratroy congestion, wheezing, and intercostal retractions. He was admitted to the hospital at that time with additional symptoms of bronchiolitis, conjunctivitis, otitis media, irritability, and poor appetite. He was initially treated with breathing treatments and intravenous antibiotics. During the course of this hospitalization he developed a diffuse urticarial rash, inflamed conjunctiva, swelling of the hands and feet, peeling skin on the feet, and red lips. His fever increased to 106 degrees, and on 28 February 2008 he was transferred to a higher level of care. Laboratory testing at that time revealed the following: CRP 273, WBC 26,000, platelets 718,000, SGOT 44; electrolytes and echocardiogram were within normal limits, and viral testing and blood cultures were negative. Cardiology was consulted, and he was diagnosed with atypical KAWASAKI's disease without evidence of cardiac lesions. He was treated with intravenous immunoglobulins and aspirin, after which he improved and was discharged to home on 03 March 2008 with instructions to follow-up for serial echocardiograms. The event was considered to be recovered.
Age: 1.0
Sex: M
Vaccine: DTAP, FLU3, HIBV, IPV, PNC, DTAP, FLU3, HIBV, IPV, PNC
Symptoms: Use of accessory respiratory muscles, Viral test negative, Wheezing, White blood cell count increased
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 306745). A one-year-old male patient received the following vaccinations on 20 February 2008: a third intramuscular injection of DAPTACEL (lot number C2800AA); a second intramuscular injection of FLUZONE No Preservative (lot number UT2459LB); a third subcutaneous injection of IPOL (lot number A0169-2); a third intramuscular injection of PREVNAR (Wyeth, lot number C45150); and a third intramuscular injection of PEDVAXHIB (Merck, lot number 0076U). The following day, the patient fell at home and hit his head, and later presented to the emergency room with a fever. The following day he presented to the emergency department again with fever (103.1) and upper respiratory infection symptoms including cough, post tussive emesis, and irritability. It was noted that he had a sick sibling at home. He was treated with intravenous antibiotics and antipyretics, and discharge to home. The next day, on 23 February 2008, he was seen by his primary care physician with respiratroy congestion, wheezing, and intercostal retractions. He was admitted to the hospital at that time with additional symptoms of bronchiolitis, conjunctivitis, otitis media, irritability, and poor appetite. He was initially treated with breathing treatments and intravenous antibiotics. During the course of this hospitalization he developed a diffuse urticarial rash, inflamed conjunctiva, swelling of the hands and feet, peeling skin on the feet, and red lips. His fever increased to 106 degrees, and on 28 February 2008 he was transferred to a higher level of care. Laboratory testing at that time revealed the following: CRP 273, WBC 26,000, platelets 718,000, SGOT 44; electrolytes and echocardiogram were within normal limits, and viral testing and blood cultures were negative. Cardiology was consulted, and he was diagnosed with atypical KAWASAKI's disease without evidence of cardiac lesions. He was treated with intravenous immunoglobulins and aspirin, after which he improved and was discharged to home on 03 March 2008 with instructions to follow-up for serial echocardiograms. The event was considered to be recovered.
Age: 1.0
Sex: M
Vaccine: DTAP, FLU3, HIBV, IPV, PNC, DTAP, FLU3, HIBV, IPV, PNC
Symptoms: Oedema peripheral, Otitis media, Platelet count increased, Pyrexia, Skin exfoliation
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 306745). A one-year-old male patient received the following vaccinations on 20 February 2008: a third intramuscular injection of DAPTACEL (lot number C2800AA); a second intramuscular injection of FLUZONE No Preservative (lot number UT2459LB); a third subcutaneous injection of IPOL (lot number A0169-2); a third intramuscular injection of PREVNAR (Wyeth, lot number C45150); and a third intramuscular injection of PEDVAXHIB (Merck, lot number 0076U). The following day, the patient fell at home and hit his head, and later presented to the emergency room with a fever. The following day he presented to the emergency department again with fever (103.1) and upper respiratory infection symptoms including cough, post tussive emesis, and irritability. It was noted that he had a sick sibling at home. He was treated with intravenous antibiotics and antipyretics, and discharge to home. The next day, on 23 February 2008, he was seen by his primary care physician with respiratroy congestion, wheezing, and intercostal retractions. He was admitted to the hospital at that time with additional symptoms of bronchiolitis, conjunctivitis, otitis media, irritability, and poor appetite. He was initially treated with breathing treatments and intravenous antibiotics. During the course of this hospitalization he developed a diffuse urticarial rash, inflamed conjunctiva, swelling of the hands and feet, peeling skin on the feet, and red lips. His fever increased to 106 degrees, and on 28 February 2008 he was transferred to a higher level of care. Laboratory testing at that time revealed the following: CRP 273, WBC 26,000, platelets 718,000, SGOT 44; electrolytes and echocardiogram were within normal limits, and viral testing and blood cultures were negative. Cardiology was consulted, and he was diagnosed with atypical KAWASAKI's disease without evidence of cardiac lesions. He was treated with intravenous immunoglobulins and aspirin, after which he improved and was discharged to home on 03 March 2008 with instructions to follow-up for serial echocardiograms. The event was considered to be recovered.
Age: 1.0
Sex: M
Vaccine: DTAP, FLU3, HIBV, IPV, PNC, DTAP, FLU3, HIBV, IPV, PNC
Symptoms: Upper respiratory tract congestion, Upper respiratory tract infection, Urticaria, Use of accessory respiratory muscles, Viral test negative
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 306745). A one-year-old male patient received the following vaccinations on 20 February 2008: a third intramuscular injection of DAPTACEL (lot number C2800AA); a second intramuscular injection of FLUZONE No Preservative (lot number UT2459LB); a third subcutaneous injection of IPOL (lot number A0169-2); a third intramuscular injection of PREVNAR (Wyeth, lot number C45150); and a third intramuscular injection of PEDVAXHIB (Merck, lot number 0076U). The following day, the patient fell at home and hit his head, and later presented to the emergency room with a fever. The following day he presented to the emergency department again with fever (103.1) and upper respiratory infection symptoms including cough, post tussive emesis, and irritability. It was noted that he had a sick sibling at home. He was treated with intravenous antibiotics and antipyretics, and discharge to home. The next day, on 23 February 2008, he was seen by his primary care physician with respiratroy congestion, wheezing, and intercostal retractions. He was admitted to the hospital at that time with additional symptoms of bronchiolitis, conjunctivitis, otitis media, irritability, and poor appetite. He was initially treated with breathing treatments and intravenous antibiotics. During the course of this hospitalization he developed a diffuse urticarial rash, inflamed conjunctiva, swelling of the hands and feet, peeling skin on the feet, and red lips. His fever increased to 106 degrees, and on 28 February 2008 he was transferred to a higher level of care. Laboratory testing at that time revealed the following: CRP 273, WBC 26,000, platelets 718,000, SGOT 44; electrolytes and echocardiogram were within normal limits, and viral testing and blood cultures were negative. Cardiology was consulted, and he was diagnosed with atypical KAWASAKI's disease without evidence of cardiac lesions. He was treated with intravenous immunoglobulins and aspirin, after which he improved and was discharged to home on 03 March 2008 with instructions to follow-up for serial echocardiograms. The event was considered to be recovered.
Age: 1.0
Sex: M
Vaccine: DTAP, FLU3, HIBV, IPV, PNC, DTAP, FLU3, HIBV, IPV, PNC
Symptoms: Vomiting, Wheezing, White blood cell count increased
Clinical narrative: This case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 306745). A one-year-old male patient received the following vaccinations on 20 February 2008: a third intramuscular injection of DAPTACEL (lot number C2800AA); a second intramuscular injection of FLUZONE No Preservative (lot number UT2459LB); a third subcutaneous injection of IPOL (lot number A0169-2); a third intramuscular injection of PREVNAR (Wyeth, lot number C45150); and a third intramuscular injection of PEDVAXHIB (Merck, lot number 0076U). The following day, the patient fell at home and hit his head, and later presented to the emergency room with a fever. The following day he presented to the emergency department again with fever (103.1) and upper respiratory infection symptoms including cough, post tussive emesis, and irritability. It was noted that he had a sick sibling at home. He was treated with intravenous antibiotics and antipyretics, and discharge to home. The next day, on 23 February 2008, he was seen by his primary care physician with respiratroy congestion, wheezing, and intercostal retractions. He was admitted to the hospital at that time with additional symptoms of bronchiolitis, conjunctivitis, otitis media, irritability, and poor appetite. He was initially treated with breathing treatments and intravenous antibiotics. During the course of this hospitalization he developed a diffuse urticarial rash, inflamed conjunctiva, swelling of the hands and feet, peeling skin on the feet, and red lips. His fever increased to 106 degrees, and on 28 February 2008 he was transferred to a higher level of care. Laboratory testing at that time revealed the following: CRP 273, WBC 26,000, platelets 718,000, SGOT 44; electrolytes and echocardiogram were within normal limits, and viral testing and blood cultures were negative. Cardiology was consulted, and he was diagnosed with atypical KAWASAKI's disease without evidence of cardiac lesions. He was treated with intravenous immunoglobulins and aspirin, after which he improved and was discharged to home on 03 March 2008 with instructions to follow-up for serial echocardiograms. The event was considered to be recovered.
Age: 49.0
Sex: F
Vaccine: FLU3
Symptoms: Anaphylactoid reaction, Asthma, Blood creatine phosphokinase normal, Blood glucose increased, Blood potassium decreased
Clinical narrative: This case was received the CDC on  03 November 2008, under VARES reference number 326677-1. A 49-year-old female received an injection of FLUZONE SV 2008-2009 (lot number U2741AA) on 23 2008 at 11:30 am. The patient later went out for lunch and ate sardines. After returning to work, she felt warm and flushed. Before leaving for home at approximately 3:30-3:45 pm, the patient went to employee health. Her face was flushed and swollen and she had hives on her neck. It was reported that the patient had no respiratory distress; however, it was also reported that the patient had some difficulty breathing. Additional reported symptoms were red face, watery eyes and dry tickle type cough. The patient was taken down the hall to ambulatory care and was seen by physician. Physical exam was positive for erythema of face and neck and mild conjunctivial edema and erythema. The patient received treatment with Benadryl, intravenous Solumedrol and oxygen, was observed, then sent home on Medrol dose pack, Benadryl and Epi-pen. Diagnosis was anaphylactoid reaction with unknown allergen. The patient's facial symptoms improved by 24 September 2008. On 26 September 2008, the patient was hospitalized for respiratory distress. She presented with increased wheezing, tachypnea, non-productive cough with chest discomfort after. Her blood glucose level was 128. She was admitted due to wheezing despite treatment with nebulizer and steroid treatment. The feeling of chest constriction continued despite treatment. Diagnosis was acute allergic reaction and asthmatic bronchitis. The patient was discharged on 28 September 2008 on Epi-pen to be used as needed, steroids, Combivent and Benadryl. Outcome was reported as "not recovered'.
Age: 49.0
Sex: F
Vaccine: FLU3
Symptoms: Carbon dioxide normal, Chest X-ray normal, Chest discomfort, Conjunctival oedema, Cough
Clinical narrative: This case was received the CDC on  03 November 2008, under VARES reference number 326677-1. A 49-year-old female received an injection of FLUZONE SV 2008-2009 (lot number U2741AA) on 23 2008 at 11:30 am. The patient later went out for lunch and ate sardines. After returning to work, she felt warm and flushed. Before leaving for home at approximately 3:30-3:45 pm, the patient went to employee health. Her face was flushed and swollen and she had hives on her neck. It was reported that the patient had no respiratory distress; however, it was also reported that the patient had some difficulty breathing. Additional reported symptoms were red face, watery eyes and dry tickle type cough. The patient was taken down the hall to ambulatory care and was seen by physician. Physical exam was positive for erythema of face and neck and mild conjunctivial edema and erythema. The patient received treatment with Benadryl, intravenous Solumedrol and oxygen, was observed, then sent home on Medrol dose pack, Benadryl and Epi-pen. Diagnosis was anaphylactoid reaction with unknown allergen. The patient's facial symptoms improved by 24 September 2008. On 26 September 2008, the patient was hospitalized for respiratory distress. She presented with increased wheezing, tachypnea, non-productive cough with chest discomfort after. Her blood glucose level was 128. She was admitted due to wheezing despite treatment with nebulizer and steroid treatment. The feeling of chest constriction continued despite treatment. Diagnosis was acute allergic reaction and asthmatic bronchitis. The patient was discharged on 28 September 2008 on Epi-pen to be used as needed, steroids, Combivent and Benadryl. Outcome was reported as "not recovered'.
Age: 49.0
Sex: F
Vaccine: FLU3
Symptoms: Dyspnoea, Erythema, Face and mouth X-ray normal, Feeling hot, Flushing
Clinical narrative: This case was received the CDC on  03 November 2008, under VARES reference number 326677-1. A 49-year-old female received an injection of FLUZONE SV 2008-2009 (lot number U2741AA) on 23 2008 at 11:30 am. The patient later went out for lunch and ate sardines. After returning to work, she felt warm and flushed. Before leaving for home at approximately 3:30-3:45 pm, the patient went to employee health. Her face was flushed and swollen and she had hives on her neck. It was reported that the patient had no respiratory distress; however, it was also reported that the patient had some difficulty breathing. Additional reported symptoms were red face, watery eyes and dry tickle type cough. The patient was taken down the hall to ambulatory care and was seen by physician. Physical exam was positive for erythema of face and neck and mild conjunctivial edema and erythema. The patient received treatment with Benadryl, intravenous Solumedrol and oxygen, was observed, then sent home on Medrol dose pack, Benadryl and Epi-pen. Diagnosis was anaphylactoid reaction with unknown allergen. The patient's facial symptoms improved by 24 September 2008. On 26 September 2008, the patient was hospitalized for respiratory distress. She presented with increased wheezing, tachypnea, non-productive cough with chest discomfort after. Her blood glucose level was 128. She was admitted due to wheezing despite treatment with nebulizer and steroid treatment. The feeling of chest constriction continued despite treatment. Diagnosis was acute allergic reaction and asthmatic bronchitis. The patient was discharged on 28 September 2008 on Epi-pen to be used as needed, steroids, Combivent and Benadryl. Outcome was reported as "not recovered'.
Age: 49.0
Sex: F
Vaccine: FLU3
Symptoms: Glucose urine present, Hypersensitivity, Lacrimation increased, Oxygen supplementation, Respiratory distress
Clinical narrative: This case was received the CDC on  03 November 2008, under VARES reference number 326677-1. A 49-year-old female received an injection of FLUZONE SV 2008-2009 (lot number U2741AA) on 23 2008 at 11:30 am. The patient later went out for lunch and ate sardines. After returning to work, she felt warm and flushed. Before leaving for home at approximately 3:30-3:45 pm, the patient went to employee health. Her face was flushed and swollen and she had hives on her neck. It was reported that the patient had no respiratory distress; however, it was also reported that the patient had some difficulty breathing. Additional reported symptoms were red face, watery eyes and dry tickle type cough. The patient was taken down the hall to ambulatory care and was seen by physician. Physical exam was positive for erythema of face and neck and mild conjunctivial edema and erythema. The patient received treatment with Benadryl, intravenous Solumedrol and oxygen, was observed, then sent home on Medrol dose pack, Benadryl and Epi-pen. Diagnosis was anaphylactoid reaction with unknown allergen. The patient's facial symptoms improved by 24 September 2008. On 26 September 2008, the patient was hospitalized for respiratory distress. She presented with increased wheezing, tachypnea, non-productive cough with chest discomfort after. Her blood glucose level was 128. She was admitted due to wheezing despite treatment with nebulizer and steroid treatment. The feeling of chest constriction continued despite treatment. Diagnosis was acute allergic reaction and asthmatic bronchitis. The patient was discharged on 28 September 2008 on Epi-pen to be used as needed, steroids, Combivent and Benadryl. Outcome was reported as "not recovered'.
Age: 49.0
Sex: F
Vaccine: FLU3
Symptoms: Swelling face, Tachypnoea, Throat irritation, Troponin T, Urticaria
Clinical narrative: This case was received the CDC on  03 November 2008, under VARES reference number 326677-1. A 49-year-old female received an injection of FLUZONE SV 2008-2009 (lot number U2741AA) on 23 2008 at 11:30 am. The patient later went out for lunch and ate sardines. After returning to work, she felt warm and flushed. Before leaving for home at approximately 3:30-3:45 pm, the patient went to employee health. Her face was flushed and swollen and she had hives on her neck. It was reported that the patient had no respiratory distress; however, it was also reported that the patient had some difficulty breathing. Additional reported symptoms were red face, watery eyes and dry tickle type cough. The patient was taken down the hall to ambulatory care and was seen by physician. Physical exam was positive for erythema of face and neck and mild conjunctivial edema and erythema. The patient received treatment with Benadryl, intravenous Solumedrol and oxygen, was observed, then sent home on Medrol dose pack, Benadryl and Epi-pen. Diagnosis was anaphylactoid reaction with unknown allergen. The patient's facial symptoms improved by 24 September 2008. On 26 September 2008, the patient was hospitalized for respiratory distress. She presented with increased wheezing, tachypnea, non-productive cough with chest discomfort after. Her blood glucose level was 128. She was admitted due to wheezing despite treatment with nebulizer and steroid treatment. The feeling of chest constriction continued despite treatment. Diagnosis was acute allergic reaction and asthmatic bronchitis. The patient was discharged on 28 September 2008 on Epi-pen to be used as needed, steroids, Combivent and Benadryl. Outcome was reported as "not recovered'.
Age: 49.0
Sex: F
Vaccine: FLU3
Symptoms: Wheezing
Clinical narrative: This case was received the CDC on  03 November 2008, under VARES reference number 326677-1. A 49-year-old female received an injection of FLUZONE SV 2008-2009 (lot number U2741AA) on 23 2008 at 11:30 am. The patient later went out for lunch and ate sardines. After returning to work, she felt warm and flushed. Before leaving for home at approximately 3:30-3:45 pm, the patient went to employee health. Her face was flushed and swollen and she had hives on her neck. It was reported that the patient had no respiratory distress; however, it was also reported that the patient had some difficulty breathing. Additional reported symptoms were red face, watery eyes and dry tickle type cough. The patient was taken down the hall to ambulatory care and was seen by physician. Physical exam was positive for erythema of face and neck and mild conjunctivial edema and erythema. The patient received treatment with Benadryl, intravenous Solumedrol and oxygen, was observed, then sent home on Medrol dose pack, Benadryl and Epi-pen. Diagnosis was anaphylactoid reaction with unknown allergen. The patient's facial symptoms improved by 24 September 2008. On 26 September 2008, the patient was hospitalized for respiratory distress. She presented with increased wheezing, tachypnea, non-productive cough with chest discomfort after. Her blood glucose level was 128. She was admitted due to wheezing despite treatment with nebulizer and steroid treatment. The feeling of chest constriction continued despite treatment. Diagnosis was acute allergic reaction and asthmatic bronchitis. The patient was discharged on 28 September 2008 on Epi-pen to be used as needed, steroids, Combivent and Benadryl. Outcome was reported as "not recovered'.
Age: 52.0
Sex: F
Vaccine: FLU3
Symptoms: Conjunctivitis, Cough, Dyspnoea, Lacrimation increased, Ocular hyperaemia
Clinical narrative: This case was received from the CDC and on 05 November 2008, under VAERS reference number 326882-1. An adult female patient between 50 - 64 years of age and who had a history of seasonal allergies (rhinitis/sinusitis), received an injection of FLUZONE SV, (lot number not reported) on 01 October 2008 and an unspecified amount of time later, developed Oculo-Respiratory Syndrome symptoms which consisted of a sore throat, cough, tightness of breath and bilateral red/tearing eyes with conjunctivitis like characteristics. The patient also complained of a  fever one hour post vaccination (100.6-101) which broke six hours after infection. Per the report, "she quoted the Guillain-Barre Syndrome." Additional medical history for the patient noted she had been menopausal. No further information was provided. Follow-up information received on 24 February 2009 via search of the VAERS database through QSCAN FDA report (VAERS ID number 326882). The vaccine administered was FLUZONE SV 2008-2009, lot number U2741AA, and it was administered intramuscularly. The adverse event of tightness of breath was reported as dyspnea. The patient experienced an additional adverse event of increased lacrimation. All adverse events began on 01 October 2008. Per the QSCAN report "She quoted the Guillain-Barre syndrome - None." The patient recovered; however a recovery date was not provided.
Age: 52.0
Sex: F
Vaccine: FLU3
Symptoms: Oculorespiratory syndrome, Oropharyngeal pain, Pyrexia
Clinical narrative: This case was received from the CDC and on 05 November 2008, under VAERS reference number 326882-1. An adult female patient between 50 - 64 years of age and who had a history of seasonal allergies (rhinitis/sinusitis), received an injection of FLUZONE SV, (lot number not reported) on 01 October 2008 and an unspecified amount of time later, developed Oculo-Respiratory Syndrome symptoms which consisted of a sore throat, cough, tightness of breath and bilateral red/tearing eyes with conjunctivitis like characteristics. The patient also complained of a  fever one hour post vaccination (100.6-101) which broke six hours after infection. Per the report, "she quoted the Guillain-Barre Syndrome." Additional medical history for the patient noted she had been menopausal. No further information was provided. Follow-up information received on 24 February 2009 via search of the VAERS database through QSCAN FDA report (VAERS ID number 326882). The vaccine administered was FLUZONE SV 2008-2009, lot number U2741AA, and it was administered intramuscularly. The adverse event of tightness of breath was reported as dyspnea. The patient experienced an additional adverse event of increased lacrimation. All adverse events began on 01 October 2008. Per the QSCAN report "She quoted the Guillain-Barre syndrome - None." The patient recovered; however a recovery date was not provided.
Age: 44.0
Sex: F
Vaccine: FLU3
Symptoms: Body temperature increased, Eye discharge, Myalgia, Ocular hyperaemia
Clinical narrative: Initial information was received on 03 November 2008 under VAERS reference number 328063-1. A 44 year old female patient received an injection of Fluzone SV (lot number U287AA) on 09 October 2008 around 5:30 pm. On 10 October 2008 at 03:00 am the patient woke up and reported experiencing really red eyes which were running and goopy, a temperatur of 102 F, and muscle aches. The patient reported that the symptoms resolved the next morning and the only residual effect was a slight headache.  The patient was reported as recovered. The patient reported having a previous reaction to a flu shot in 2006 (manufacturer not reported) which similar to reaction that occurred on 10 October 2008.